According to a survey conducted in 2023, 38 percent of biopharma executives whose companies are outsourcing stated that the full-service model is their current outsourcing model of clinical development work. The full-service model was more common among small and mid-sized companies (40 percent) than among large companies (35 percent). This statistic describes the distribution of outsourcing models in clinical development among biopharmaceutical companies worldwide, by size of the company.
Percentage of outsourcing models in clinical development among biopharmaceutical companies worldwide as of 2023, by company size
Characteristic
Insourcing/temp. staff
Hybrid
Functional service provider (FSP)
Full-service
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Exclusive Premium Statistic
To access all Premium Statistics, you need a paid Statista Account
respondents from large companies: n=65, from small/mid: n=85
Method of interview
Panel survey
Supplementary notes
The respondents are working for pharma, biopharma, or
biotech companies; they have drug development decision-making responsibility and
are director-level or above; they work in a role related to drug development; their companies have at least one compound in development; they are from the US/Canada, Europe, and Asia.
Original question: "For the areas in your company with which you are familiar, what percent of current clinical development work that is outsourced is accomplished via the following outsourcing models?"
Percentage points missing/exceeding 100 percent are probably due to rounding.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Thermo Fisher (PPD). (September 12, 2023). Percentage of outsourcing models in clinical development among biopharmaceutical companies worldwide as of 2023, by company size [Graph]. In Statista. Retrieved July 23, 2024, from https://www.statista.com/statistics/1414480/biopharmaceutical-companies-outsourcing-models-by-company-size/
Thermo Fisher (PPD). "Percentage of outsourcing models in clinical development among biopharmaceutical companies worldwide as of 2023, by company size." Chart. September 12, 2023. Statista. Accessed July 23, 2024. https://www.statista.com/statistics/1414480/biopharmaceutical-companies-outsourcing-models-by-company-size/
Thermo Fisher (PPD). (2023). Percentage of outsourcing models in clinical development among biopharmaceutical companies worldwide as of 2023, by company size. Statista. Statista Inc.. Accessed: July 23, 2024. https://www.statista.com/statistics/1414480/biopharmaceutical-companies-outsourcing-models-by-company-size/
Thermo Fisher (PPD). "Percentage of Outsourcing Models in Clinical Development among Biopharmaceutical Companies Worldwide as of 2023, by Company Size." Statista, Statista Inc., 12 Sep 2023, https://www.statista.com/statistics/1414480/biopharmaceutical-companies-outsourcing-models-by-company-size/
Thermo Fisher (PPD), Percentage of outsourcing models in clinical development among biopharmaceutical companies worldwide as of 2023, by company size Statista, https://www.statista.com/statistics/1414480/biopharmaceutical-companies-outsourcing-models-by-company-size/ (last visited July 23, 2024)
Percentage of outsourcing models in clinical development among biopharmaceutical companies worldwide as of 2023, by company size [Graph], Thermo Fisher (PPD), September 12, 2023. [Online]. Available: https://www.statista.com/statistics/1414480/biopharmaceutical-companies-outsourcing-models-by-company-size/